Table 2.

Comparison of tolerability and duration of therapy in DT $\ge$ 1 and DT < 1 cohorts.

N = 138 [blood tests not available for one patient]	N	DT $\ge$ 1 (N = 61)	DT < 1 (N = 77)	Chi-square/Fisher's Exact p value
Hemoglobin g/dl nadir
<8	34	22 (36%)	12 (16%)	0.010
$\ge$ 8	104	39 (64%)	65 (84%)
Absolute neutrophil count (ANC)/dl nadir
<1000	10	7 (11%)	3 (4%)	0.10
$\ge$ 1000	128	54 (89%)	74 (96%)
Platelet/dl nadir
<50,000	6	4 (3%)	2 (3%)	0.41
$\ge$ 50,000	132	57 (93%)	75 (93%)
Olaparib dose reduction
Yes	30	14 (23%)	16 (21%)	0.96
No	109	48 (77%)	61 (79%)
Duration of olaparib therapy
Days (median, IQR)		204 (127–319)	103 (72–158)	<0.0001